Sebastian Zundler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7606527/publications.pdf

Version: 2024-02-01

44 papers	1,470 citations	331670 21 h-index	330143 37 g-index
46 all docs	46 docs citations	46 times ranked	1978 citing authors

#	Article	IF	Citations
1	Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut, 2023, 72, 49-53.	12.1	18
2	Residual homing of Î±4Î²7-expressing Î²1⁺PI16⁺ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut, 2022, 71, 1551-1566.	12.1	24
3	Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. Gut, 2022, 71, 2414-2429.	12.1	26
4	Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets. Clinical and Translational Gastroenterology, 2022, 13, e00494.	2.5	5
5	Vedolizumab blocks Î±4Î²7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210988.	3.2	3
6	Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflammatory Bowel Diseases, 2022, 28, 1746-1755.	1.9	5
7	Severe Acute Respiratory Syndrome Coronavirus 2 Attachment Receptor Angiotensin-Converting Enzyme 2 Is Decreased in Crohnâ€™s Disease and Regulated By Microbial and Inflammatory Signaling. Gastroenterology, 2021, 160, 925-928.e4.	1.3	15
8	Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482098280.	3.2	14
9	Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterology, 2021, 21, 33.	2.0	10
10	Intestinal Mucosal Wound Healing and Barrier Integrity in IBDâ€“Crosstalk and Trafficking of Cellular Players. Frontiers in Medicine, 2021, 8, 643973.	2.6	52
11	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker Î±4Î²7 Integrin Are Decreased in COVID-19. Frontiers in Immunology, 2021, 12, 639329.	4.8	8
12	Vedolizumab-associated enthesitis: correlation or causality?. Rheumatology, 2021, 60, 5491-5492.	1.9	2
13	Targeting Immune Cell Trafficking â€“ Insights From Research Models and Implications for Future IBD Therapy. Frontiers in Immunology, 2021, 12, 656452.	4.8	17
14	Dynamic Imaging of IEL-IEC Co-Cultures Allows for Quantification of CD103-Dependent T Cell Migration. International Journal of Molecular Sciences, 2021, 22, 5148.	4.1	5
15	E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis. Nature Cell Biology, 2021, 23, 796-807.	10.3	38
16	Î±4Î²7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110547.	3.2	1
17	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open, 2021, 11, e049208.	1.9	9
18	Non-classical monocyte homing to the gut via Î±4Î²7 integrin mediates macrophage-dependent intestinal wound healing. Gut, 2020, 69, 252-263.	12.1	80

#	Article	IF	Citations
19	Utilization of Diagnostic Imaging and Ionizing Radiation Exposureâ€"Has the Tide Already Turned?. Inflammatory Bowel Diseases, 2020, 26, 907-908.	1.9	0
20	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 508-524.	1.3	46
21	Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications. Visceral Medicine, 2020, 36, 129-136.	1.3	5
22	Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterology, 2020, 20, 103.	2.0	12
23	Total Recall: Intestinal TRM Cells in Health and Disease. Frontiers in Immunology, 2020, 11, 623072.	4.8	8
24	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 39.	3.5	25
25	Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut, 2019, 68, 1688-1700.	12.1	108
26	Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology, 2019, 35, 499-506.	2.3	2
27	Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. Journal of Visualized Experiments, 2018, , .	0.3	3
28	Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application. American Journal of Gastroenterology, 2018, 113, 1908-1910.	0.4	9
29	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases, 2018, 24, 1237-1250.	1.9	33
30	BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 916-930.	8.2	34
31	Blockade of Î±EÎ²7 integrin suppresses accumulation of CD8⁺and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut, 2017, 66, 1936-1948.	12.1	99
32	The Î±4Î²1 Homing Pathway Is Essential for Ileal Homing of CrohnÊ¼s Disease Effector T Cells In Vivo. Inflammatory Bowel Diseases, 2017, 23, 379-391.	1.9	88
33	Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2017, 23, 617-627.	1.9	39
34	Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. Gastroenterology, 2017, 153, 898-900.	1.3	27
35	Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. Immunological Reviews, 2017, 278, 263-276.	6.0	20
36	Pancreatic Panniculitis and Polyarthritis. Current Rheumatology Reports, 2017, 19, 62.	4.7	23

#	Article	IF	Citations
37	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Frontiers in Immunology, 2017, 8, 764.	4.8	42
38	Anti-Adhesion Therapies in Inflammatory Bowel Diseaseâ€"Molecular and Clinical Aspects. Frontiers in Immunology, 2017, 8, 891.	4.8	52
39	Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. Vaccines, 2016, 4, 5.	4.4	64
40	Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver â€“ case report and review of literature. BMC Cancer, 2016, 16, 130.	2.6	38
41	How will new and future therapies change our treatment of IBD?. Expert Review of Clinical Immunology, 2016, 12, 233-236.	3.0	3
42	Differential effects of Î±4Î²7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut, 2016, 65, 1642-1664.	12.1	138
43	Interleukin-12: Functional activities and implications for disease. Cytokine and Growth Factor Reviews, 2015, 26, 559-568.	7.2	178
44	Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clinical and Experimental Rheumatology, 2015, 33, S19-28.	0.8	36